TOI Q2 revenue up 32% to $80M, net loss widens to $16.9M, reaffirms FY 2023 guidance

Oncology Institute, Inc.

2023-Q2 EPS reported -$0.52 revenue$156,416,000

Revenue of $80M (+32% YoY); gross profit $15M (+36%); gross margin 18.8% vs 18.3%.
Net loss of $16.9M vs $5.5M loss in prior year; EPS $(0.19) vs $(0.06).
Adjusted EBITDA $(6.9)M, flat YoY; cash & investments $98M as of June 30, 2023.
Acquired Southland Radiation Oncology Network; patient visits up 14%, oral drugs dispensed up 38% YoY.
Reaffirmed full-year 2023 guidance; management cites strong topline growth and momentum.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oncology Institute, Inc. updated its three months ended June 30, 2023 guidance (reaffirmed).

Period: three months ended June 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On August 8, 2023, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2023 and certain other financial information.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001799191-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.